Corona virus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. At present, there is no specific antiviral drug for this virus, and the main clinical treatment is support and symptomatic treatment. Direct targeting the virus and the host targets are two strategies for the development of antiviral drugs. At present, the research and development of COVID-19 therapeutic drugs has made some progress on both approaches. Here we review potential anti-SARS-CoV-2 drugs to discuss the antiviral mechanisms and potential of these drugs from the perspectives of virus and host. The role of traditional Chinese medicine in the treatment of COVID-19 is discussed along with the prospects for drug treatment strategies of COVID-19.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |